FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA draft guidance lays out use of pathologic complete response to support accelerated approval of drugs for women with high-risk, early-stage breast cancer. Pathway allows for initial approval based on one pivotal study, which could be extended to assess survival and confirm clearance.
You may also be interested in...
Bladder Cancer: More Questions Than Answers With pCR Endpoint
Pathologic complete response eventually may be a surrogate endpoint for survival, but researchers and the US FDA outlined several problems that must be resolved first.
Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate
More work needs to be done to validate MRD as predictive of clinical outcomes in hematological malignancies before it can be used as the basis for accelerated approval, FDA and other stakeholders say.
Genetic Exposé Of Ovarian Cancer Prompts Radical Rethink Of Trial Design
Whereas Phase III cancer trials are currently randomized and involve hundreds of patients, some experts say small trials with from 20 to 50 patients make more sense for targeted drugs in ovarian cancer, considering the genetic diversity of this already uncommon disease.